Zhi Tong Cai Jing·2025-09-15 08:01Core Viewpoint - The Trump administration's health officials plan to present claims linking COVID-19 vaccines to 25 child deaths to a key vaccine advisory committee, impacting biotech stocks negatively [1] Group 1: Impact on Biotech Stocks - Following the news, U.S. biotech stocks experienced significant declines, with BioNTech down 7.26%, Pfizer down 3.98%, Moderna down 7.40%, and Novavax down 3.62% [1] - Citigroup highlighted the volatility risk for biotech companies due to the news, emphasizing the robust research supporting COVID-19 vaccines and billions of doses administered [1] Group 2: Company Ratings by Citigroup - BioNTech: Rated "Buy" with a target price of $140, but considered "high risk" due to typical volatility in biotech stocks and uncertainties in clinical trials [3] - Moderna: Rated "Neutral" with a target price of $30, also deemed "high risk" with potential down risks related to market stability and product effectiveness [4] - Novavax: Rated "Sell" with a target price of $6, facing risks but with potential upside if the COVID-19 vaccine market recovers unexpectedly [5] - Pfizer: Target price set at $26, with both upside and downside risks related to new drug sales and competitive pressures [6]